Normal View Dyslexic View

Trimodality therapy versus perioperative chemotherapy in  the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (NEO-AEGIS): an open-label, randomised, phase 3 trial.

24 January 2024
Randomized clinical trials Upper GI
Reynolds JV, Preston SR, O’Neill B, Lowery MA, Baeksgaard  L, Crosby T et al, on behalf of the Neo-AEGIS Investigators and trial group.

Lancet Gastrohepatol 2023; 8: 1015-1027.

Some 362 patients were available for analysis after a median of 38.8 months. Overall survival was 48 months after perioperative chemotherapy versus 49.2 months after trimodality therapy; hazard ratio 1.03, 95 per cent confidence interval 0.77 to 1.38; P=0.82.

Comment: Disappointing result, and calls into question the role of radiotherapy for this condition.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
Info
Copied!